bob
I thought the same thing as you when I saw the reuters article. At first I thought the company sent out a P/R, and I said why is he sending out a press release saying he will issue a press release with new data. Then I realized it was a rueters interview. If Reuters called him to respond to the weak data or to ask about further progress towards the approval of the neutraceuticals in Europe and he mentioned that the data isn't as bad as the market perceived, than he did the right thing.
By the way, the stock should never have gotten as high as it did, because there was no human data to give any one the idea that the drug would match up well against Zetia. Since the data is out, the stock is worth more now that it was before, because it actually has a shot.
Market Data 
Markets 
AI
